Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-13

Clinical Trial Update: TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM) [Phase 2]

View source ↗

Summary

A Phase 2 trial of TRX4 monoclonal antibody for Type 1 diabetes was terminated. The results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRX4 Monoclonal Antibody (TRX4)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: TERMINATED | Results posted: 2017-11-13